Risteys FinnGen R7

Summary Statistics

↥

Key figures

All

Female

Male

Number of individuals

2798

1486

1312

Unadjusted prevalence (%)

0.91

0.86

0.97

Mean age at first event (years)

48.74

46.98

50.73

?

Follow-up

Amount of time to look for the endpoint since entering the study. This is either either 1, 5, 15 years or the full study time from 1998 to 2019.

Absolute risk

Estimates the probability of dying from the current endpoint. Check the Documentation page for Mortality: absolute risk to get more details.

Hazard Ratio (HR) and 95% Confidence Interval (CI)

Measures how much the risk of dying increases (HR > 1) or decreases (HR < 1).

Number of individuals (N)

Number of individuals having the current endpoint and died during the follow-up time.
Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	0.07	5.90 [2.65, 13.10]	1.3e-5	221
15 years	0.01	1.72 [0.75, 3.94]	2.0e-1	60
5 years	0.01	9.63 [5.61, 16.54]	2.2e-16	101
1 year	0.00	21.01 [13.07, 33.78]	3.2e-36	51

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: OPER_SFA – Direct fill therapy
GWS hits:

Survival analyses between endpoints

↥

Plot

before Direct fill therapy
after Direct fill therapy

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Direct fill therapy

↥

≡ Risteys

R7

R3

R4

R5

R6

Direct fill therapy

Endpoint definition

Similar endpoints

Summary Statistics

Key figures

Number of individuals

Unadjusted prevalence

Mean age at first event

Follow-up

Absolute risk

Hazard Ratio (HR) and 95% Confidence Interval (CI)

Number of individuals (N)